Free Trial
→ A new income category is drawing serious money - here's why (From Investors Alley) (Ad)tc pixel
OTCMKTS:GNMSF

Genmab A/S Q4 2025 Earnings Results & Report

Genmab A/S logo
$367.00 0.00 (0.00%)
As of 10/9/2026 10:28 AM Eastern

Genmab A/S missed analyst earnings expectations but beat on revenue in its Q4 2025 results, released February 17, 2026. The company reported EPS of $0.55 versus the $3.10 consensus estimate, while revenue of $1.06 billion topped the $1.05 billion estimate by $5.60 million.

Research:ProfileEarnings History

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens

Genmab A/S EPS Results

Actual EPS
$0.55
Consensus EPS
$3.10
Beat/Miss
Missed by -$2.55
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 5 quarters

Genmab A/S Revenue Results

Actual Revenue
$1.06 billion
Expected Revenue
$1.05 billion
Beat/Miss
Beat by +$5.60 million
YoY Revenue Growth
N/A

Upcoming Earnings

Genmab A/S' next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules.

Conference Call Resources

Genmab A/S Q4 2025 Earnings FAQ

Genmab A/S (OTCMKTS:GNMSF) reported earnings of $0.55 per share for Q4 2025, missing the consensus estimate of $3.10. The report was announced on Tuesday, February 17, 2026.

Genmab A/S reported revenue of $1.06 billion for Q4 2025, against a consensus estimate of $1.05 billion.

Genmab A/S' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Genmab A/S on the company's earnings history page.

Genmab A/S Earnings Headlines

Genmab Grants Restricted Stock Units to Board After Extraordinary General Meeting
October 7, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/genmab-grants-restricted-stock-units-to-board-after-extraordinary-general-meeting?utm_source=marketbeat.com&utm_medium=referral
Genmab A/S (OTCMKTS:GNMSF) Shares Gap Up - Here's What Happened
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31092515
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.tc pixel
October 12 at 1:00 AM  |  Banyan Hill Publishing (Ad)
GMAB jumps as Genmab posts positive Phase 3 lymphoma data
October 5, 2026  |  quiverquant.comQ
Genmab A/S (OTCMKTS:GNMSF) Sets New 12-Month High - What's Next?
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31087873
Genmab Discloses Darwin Global as 5.11% Major Shareholder
October 2, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/genmab-discloses-darwin-global-as-5-11-major-shareholder?utm_source=marketbeat.com&utm_medium=referral
See More Genmab A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genmab A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genmab A/S and other key companies, straight to your email.

About Genmab A/S

Genmab A/S (OTCMKTS:GNMSF) is a Danish biotechnology company focused on discovering, developing and commercializing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company develops therapeutic antibodies and antibody formats designed to engage the immune system, target disease-specific biology and potentially improve treatment outcomes.

Genmab’s technology platforms include DuoBody, which enables the development of bispecific antibodies, as well as HexaBody and other antibody-engineering technologies. Its research and development activities have contributed to medicines including DARZALEX (daratumumab) for multiple myeloma, RYBREVANT (amivantamab) for certain lung cancers, and EPKINLY (epcoritamab) for certain B-cell lymphomas. Genmab has developed these and other products through collaborations with global pharmaceutical companies, including Johnson & Johnson and AbbVie.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab serves international markets through research, development, partnerships and commercialization activities in Europe, North America and other regions. The company is led by President and Chief Executive Officer Jan van de Winkel, who has been associated with Genmab’s leadership since the company’s early development.

View Genmab A/S Profile
Earnings Tools